HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
50 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
FUS
FUS RNA binding protein
Chromosome 16 Β· 16p11.2
NCBI Gene: 2521Ensembl: ENSG00000089280.20HGNC: HGNC:4010UniProt: A0AAQ5BIG2
757PubMed Papers
23Diseases
0Drugs
50Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub GeneOncogene
RESEARCH IMPACT
Highly StudiedTrending
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
mRNA stabilizationregulation of DNA-templated transcriptionregulation of transcription by RNA polymerase IIRNA splicingsporadic amyotrophic lateral sclerosisessential tremoramyotrophic lateral sclerosisfrontotemporal dementia with motor neuron disease
✦AI Summary

FUS (fused in sarcoma) is a multifunctional RNA-binding protein that plays critical roles in cellular homeostasis and disease pathogenesis. The protein undergoes liquid-liquid phase separation (LLPS) to form membraneless organelles essential for various cellular processes 1. FUS is crucial for DNA repair initiation, where its LLPS activity is necessary for recruiting DNA damage response factors including KU80, NBS1, and 53BP1 to damage sites 2. In healthy neurons, FUS maintains axonal and synaptic function through regulation of mRNA localization, transport, and local translation 3. The protein's nuclear localization is regulated by its import receptor Transportin and arginine methylation, which also suppress pathological phase separation 4. Mutations in FUS cause familial amyotrophic lateral sclerosis (ALS6), characterized by early onset (average 35.2 years) and aggressive progression 5. These mutations disrupt nuclear import, leading to cytoplasmic accumulation and formation of pathological aggregates 6. ALS-associated FUS mutations also alter stress granule composition and dynamics, creating more unstructured, AU-rich transcriptomes that may contribute to neurodegeneration 7. Therapeutically, antisense oligonucleotide-mediated FUS silencing shows promise in reducing protein aggregates and delaying motor neuron degeneration 8.

Sources cited
1
FUS undergoes liquid-liquid phase separation to form membraneless organelles
PMID: 33446423
2
FUS LLPS is necessary for DNA repair initiation and recruitment of damage response factors
PMID: 33704371
3
FUS maintains axonal and synaptic function through mRNA regulation
PMID: 36963381
4
Transportin and arginine methylation regulate FUS nuclear localization and suppress pathological phase separation
PMID: 29677514
5
FUS mutations cause ALS6 with early onset and aggressive progression
PMID: 37926865
6
FUS mutations cause familial ALS and lead to cytoplasmic protein accumulation
PMID: 19251627
7
ALS-associated FUS mutations alter stress granule composition and dynamics
PMID: 39494508
8
Antisense oligonucleotide FUS silencing shows therapeutic promise
PMID: 35075293
Disease Associationsβ“˜23
sporadic amyotrophic lateral sclerosisOpen Targets
0.81Strong
essential tremorOpen Targets
0.72Strong
amyotrophic lateral sclerosisOpen Targets
0.71Strong
frontotemporal dementia with motor neuron diseaseOpen Targets
0.66Moderate
juvenile amyotrophic lateral sclerosisOpen Targets
0.52Moderate
genetic disorderOpen Targets
0.42Moderate
amyotrophic lateral sclerosis, dominantOpen Targets
0.41Moderate
liposarcomaOpen Targets
0.38Weak
undifferentiated pleomorphic sarcomaOpen Targets
0.37Weak
synovial sarcomaOpen Targets
0.37Weak
extraskeletal myxoid chondrosarcomaOpen Targets
0.37Weak
myxofibrosarcomaOpen Targets
0.37Weak
congenital fibrosarcomaOpen Targets
0.37Weak
nodular fasciitisOpen Targets
0.37Weak
well-differentiated liposarcomaOpen Targets
0.37Weak
leiomyosarcomaOpen Targets
0.37Weak
lipomaOpen Targets
0.37Weak
myxomaOpen Targets
0.37Weak
dedifferentiated liposarcomaOpen Targets
0.37Weak
mixed liposarcomaOpen Targets
0.37Weak
Amyotrophic lateral sclerosis 6, with or without frontotemporal dementiaUniProt
Angiomatoid fibrous histiocytomaUniProt
Tremor, hereditary essential 4UniProt
Pathogenic Variants50
NM_004960.4(FUS):c.1561C>T (p.Arg521Cys)Pathogenic
Amyotrophic lateral sclerosis type 6|not provided|Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4|FUS-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 521
NM_004960.4(FUS):c.1574C>T (p.Pro525Leu)Pathogenic
not provided|Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4|Juvenile amyotrophic lateral sclerosis|FUS-related disorder|Amyotrophic lateral sclerosis type 6
β˜…β˜…β˜†β˜†2025β†’ Residue 525
NM_004960.4(FUS):c.1540A>G (p.Arg514Gly)Pathogenic
Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4|Amyotrophic lateral sclerosis type 6
β˜…β˜…β˜†β˜†2025β†’ Residue 514
NM_004960.4(FUS):c.1509_1510del (p.Gly504fs)Pathogenic
Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4|Amyotrophic lateral sclerosis type 6|not provided|FUS-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 504
NM_004960.4(FUS):c.1408del (p.Asp470fs)Pathogenic
not provided|Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4
β˜…β˜…β˜†β˜†2025β†’ Residue 470
NM_004960.4(FUS):c.1562G>A (p.Arg521His)Pathogenic
Amyotrophic lateral sclerosis type 6|Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 521
NM_004960.4(FUS):c.1504del (p.Asp502fs)Pathogenic
Inborn genetic diseases|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 502
NM_004960.4(FUS):c.1528A>G (p.Lys510Glu)Pathogenic
Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 510
NM_004960.4(FUS):c.1561C>G (p.Arg521Gly)Pathogenic
Amyotrophic lateral sclerosis type 6|Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4|FUS-related disorder|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 521
NM_004960.4(FUS):c.1483C>T (p.Arg495Ter)Pathogenic
Amyotrophic lateral sclerosis type 6|not provided|Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4
β˜…β˜…β˜†β˜†2023β†’ Residue 495
NM_004960.4(FUS):c.1554_1557del (p.Gln519fs)Pathogenic
Tremor, hereditary essential, 4;Amyotrophic lateral sclerosis type 6|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 519
NM_004960.4(FUS):c.1562G>T (p.Arg521Leu)Pathogenic
Amyotrophic lateral sclerosis type 6|Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4
β˜…β˜…β˜†β˜†2022β†’ Residue 521
NM_004960.4(FUS):c.1394-2delPathogenic
not provided|Amyotrophic lateral sclerosis type 6|Tremor, hereditary essential, 4;Amyotrophic lateral sclerosis type 6|FUS-related disorder
β˜…β˜…β˜†β˜†2022
NM_004960.4(FUS):c.1564A>G (p.Arg522Gly)Likely pathogenic
Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4|Amyotrophic lateral sclerosis type 6
β˜…β˜†β˜†β˜†2026β†’ Residue 522
NM_004960.4(FUS):c.1441C>T (p.Arg481Ter)Pathogenic
Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4
β˜…β˜†β˜†β˜†2025β†’ Residue 481
NM_004960.4(FUS):c.1483dup (p.Arg495fs)Likely pathogenic
Nanophthalmos 4
β˜…β˜†β˜†β˜†2025β†’ Residue 495
NM_004960.4(FUS):c.1526G>A (p.Gly509Asp)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 509
NM_004960.4(FUS):c.1496dup (p.Gly500fs)Likely pathogenic
Amyotrophic lateral sclerosis type 6
β˜…β˜†β˜†β˜†2025β†’ Residue 500
NM_004960.4(FUS):c.1561C>A (p.Arg521Ser)Pathogenic
Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4
β˜…β˜†β˜†β˜†2025β†’ Residue 521
NM_004960.4(FUS):c.1496del (p.Gly499fs)Pathogenic
Amyotrophic lateral sclerosis type 6;Tremor, hereditary essential, 4
β˜…β˜†β˜†β˜†2024β†’ Residue 499
View on ClinVar β†—
Related Genes
HNRNPA2B1Protein interaction100%DROSHAProtein interaction100%CAPRIN1Protein interaction100%NEFHProtein interaction100%TIAL1Protein interaction100%DICER1Protein interaction100%
Tissue Expression6 tissues
Bone Marrow
100%
Ovary
78%
Brain
44%
Lung
41%
Heart
33%
Liver
29%
Gene Interaction Network
Click a node to explore
FUSHNRNPA2B1DROSHACAPRIN1NEFHTIAL1DICER1
PROTEIN STRUCTURE
Preparing viewer…
PDB6KJ3 Β· 0.60 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.10Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.04 [0.02–0.10]
RankingsWhere FUS stands among ~20K protein-coding genes
  • #269of 20,598
    Most Researched757 Β· top 5%
  • #1,321of 5,498
    Most Pathogenic Variants50 Β· top quartile
  • #69of 17,882
    Most Constrained (LOEUF)0.10 Β· top 1%
Genes detectedFUS
Sources retrieved50 papers
Response timeβ€”
πŸ“„ Sources
50β–Ό
1
FUS and TDP-43 Phases in Health and Disease.
PMID: 33446423
Trends Biochem Sci Β· 2021
1.00
2
PMID: 37926865
Amyotroph Lateral Scler Frontotemporal Degener Β· 2024
0.90
3
M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development.
PMID: 40700505
Sci Adv Β· 2025
0.88
4
Single-cell RNA-sequencing reveals early mitochondrial dysfunction unique to motor neurons shared across FUS- and TARDBP-ALS.
PMID: 40389397
Nat Commun Β· 2025
0.82
5
FUS::DDIT3 Fusion Protein in the Development of Myxoid Liposarcoma and Possible Implications for Therapy.
PMID: 39456230
Biomolecules Β· 2024
0.80